Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

2
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
2
Hematopoiesis01:21

Hematopoiesis

5.1K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
5.1K
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

3.0K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.0K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

3.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.2K
Production of Formed Elements01:34

Production of Formed Elements

1.3K
Hemangioblasts are multipotent stem cells originating from the mesoderm. They give rise to hematopoietic stem cells (HSCs), which undergo hematopoiesis to produce all the formed elements of blood. This process is regulated by a complex network of hematopoietic growth factors, including transcription factors, growth factors, and cytokines. These factors stimulate the HSCs to divide and differentiate, though some HSCs remain undifferentiated to maintain a self-renewing pool.
Most HSCs commit to...
1.3K
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

3
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
3

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Utility of genetic screening for the prediction of severe arrhythmic outcomes in mitral valve prolapse.

medRxiv : the preprint server for health sciences·2026
Same author

Clonal hematopoiesis of indeterminate potential and heart disease: What every internist needs to know.

Cleveland Clinic journal of medicine·2026
Same author

Gamut of Patients Referred to Cardiology for Question of Clonal Hematopoiesis.

Circulation. Genomic and precision medicine·2026
Same author

Wondering Y: How Might Loss of the Y Chromosome Promote Cardiovascular Disease in Aging Men?

Journal of the American College of Cardiology·2026
Same author

Genomic and transcriptomic analyses of aortic stenosis enhance therapeutic target discovery and disease prediction.

Nature genetics·2025
Same author

Incorporating Management of Clonal Hematopoiesis of Indeterminate Potential Into Cardiovascular Practice.

Circulation·2025

相关实验视频

Updated: Jun 11, 2025

Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis
08:00

Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis

Published on: May 26, 2021

12.4K

克隆性血液形成和动脉样硬化

Ohad Oren1, Aeron M Small2, Peter Libby2

  • 1Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.

The Journal of clinical investigation
|October 1, 2024
PubMed
概括

在衰老中常见的不确定潜力的克隆性血液形成 (CHIP) 是心血管疾病的重要危险因素,超出了癌症风险. 某些CHIP突变通过不同的炎症途径加速动脉样硬化,指导个性化治疗.

科学领域:

  • 血液学 血液学 血液学
  • 心血管医学 心血管医学
  • 遗传学 遗传学是一种遗传学.

背景情况:

  • 不确定潜力的克隆性血液形成 (CHIP) 涉及白血病驱动基因的体质突变,在外周血液中产生突变细胞克隆.
  • CHIP是一种新兴的,常见的,与年龄相关的动脉样硬化风险因素,导致超出血液恶性瘤风险的过度死亡率.

研究的目的:

  • 研究CHIP突变在加速动脉样硬化中的因果作用.
  • 探索不同的CHIP相关突变如何对动脉样硬化事件和病理生理学产生不同影响.
  • 了解针对性治疗和个性化医学的影响.

主要方法:

  • 对将CHIP突变与动脉样硬化联系起来的实验证据的分析.
  • 对不同CHIP突变类型 (例如DNMT3a与TET2/JAK2) 的异源性进行比较评估.

主要成果:

  • 特定的CHIP突变与加速动脉样硬化有因果关系.
  • 由于TET2或JAK2突变导致的CHIP通过炎症促进动脉样硬化,与DNMT3a突变不同.
  • CHIP的心血管风险因潜在的基因驱动突变而异.

结论:

更多相关视频

Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models
08:14

Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models

Published on: October 3, 2019

12.1K
A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology
05:51

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology

Published on: May 6, 2014

13.1K

相关实验视频

Last Updated: Jun 11, 2025

Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis
08:00

Bone Marrow Transplantation Procedures in Mice to Study Clonal Hematopoiesis

Published on: May 26, 2021

12.4K
Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models
08:14

Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models

Published on: October 3, 2019

12.1K
A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology
05:51

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology

Published on: May 6, 2014

13.1K
  • CHIP是心血管疾病的重要驱动因素,基于突变类型的独特致病机制.
  • 了解这些机制为CHIP患者的向治疗开辟了道路.
  • 这项研究推进了个性化医疗方法来管理CHIP相关的心血管风险.